Opportunities and challenges following approval of resmetirom for MASH liver disease

Jeffrey V. Lazarus (Lead / Corresponding author), Dana Ivancovsky Wajcman, Henry E. Mark, Zobair M. Younossi, Christopher J. Kopka, Nevin Cohen, Meena B. Bansal, Michael Betel, Paul N. Brennan

    Research output: Contribution to journalComment/debate

    3 Citations (Scopus)

    Abstract

    The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.
    Original languageEnglish
    Number of pages4
    JournalNature Medicine
    Early online date19 Apr 2024
    DOIs
    Publication statusE-pub ahead of print - 19 Apr 2024

    Keywords

    • Drug regulation
    • Health policy
    • Non-alcoholic fatty liver disease
    • Non-alcoholic steatohepatitis
    • Public health

    Fingerprint

    Dive into the research topics of 'Opportunities and challenges following approval of resmetirom for MASH liver disease'. Together they form a unique fingerprint.

    Cite this